Benjamin Hohl's most recent trade in Enliven Therapeutics Inc was a trade of 3,250 Common Stock done at an average price of $20.6 . Disclosure was reported to the exchange on Aug. 27, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Enliven Therapeutics Inc | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 20.63 per share. | 27 Aug 2025 | 3,250 | 23,000 | - | 20.6 | 67,039 | Common Stock |
| Enliven Therapeutics Inc | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Aug 2025 | 3,250 | 108,306 | - | - | Stock Option (right to buy) | |
| Enliven Therapeutics Inc | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.48 per share. | 27 Aug 2025 | 3,250 | 26,250 | - | 2.5 | 8,060 | Common Stock |
| Enliven Therapeutics Inc | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Jul 2025 | 3,250 | 111,556 | - | - | Stock Option (right to buy) | |
| Enliven Therapeutics Inc | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.48 per share. | 28 Jul 2025 | 3,250 | 26,250 | - | 2.5 | 8,060 | Common Stock |
| Enliven Therapeutics Inc | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 20.45 per share. | 28 Jul 2025 | 3,185 | 23,065 | - | 20.4 | 65,119 | Common Stock |
| Enliven Therapeutics Inc | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 21.31 per share. | 28 Jul 2025 | 65 | 23,000 | - | 21.3 | 1,385 | Common Stock |
| Enliven Therapeutics Inc | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 22.66 per share. | 10 Jul 2025 | 1,000 | 23,000 | - | 22.7 | 22,655 | Common Stock |
| Enliven Therapeutics Inc | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jul 2025 | 1,000 | 114,806 | - | - | Stock Option (right to buy) | |
| Enliven Therapeutics Inc | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.48 per share. | 10 Jul 2025 | 1,000 | 24,000 | - | 2.5 | 2,480 | Common Stock |
| Enliven Therapeutics Inc | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Jun 2025 | 3,250 | 115,806 | - | - | Stock Option (right to buy) | |
| Enliven Therapeutics Inc | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.48 per share. | 27 Jun 2025 | 3,250 | 26,250 | - | 2.5 | 8,060 | Common Stock |
| Enliven Therapeutics Inc | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 20.86 per share. | 27 Jun 2025 | 3,052 | 23,198 | - | 20.9 | 63,667 | Common Stock |
| Enliven Therapeutics Inc | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 21.66 per share. | 27 Jun 2025 | 198 | 23,000 | - | 21.7 | 4,288 | Common Stock |
| Enliven Therapeutics Inc | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.48 per share. | 13 Jun 2025 | 3,000 | 26,000 | - | 2.5 | 7,440 | Common Stock |
| Enliven Therapeutics Inc | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jun 2025 | 3,000 | 119,056 | - | - | Stock Option (right to buy) | |
| Enliven Therapeutics Inc | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 22.55 per share. | 13 Jun 2025 | 3,000 | 23,000 | - | 22.6 | 67,655 | Common Stock |
| Enliven Therapeutics Inc | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 May 2025 | 3,250 | 122,056 | - | - | Stock Option (right to buy) | |
| Enliven Therapeutics Inc | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 16.18 per share. | 27 May 2025 | 3,250 | 23,000 | - | 16.2 | 52,593 | Common Stock |
| Enliven Therapeutics Inc | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.48 per share. | 27 May 2025 | 3,250 | 26,250 | - | 2.5 | 8,060 | Common Stock |
| Enliven Therapeutics Inc | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Apr 2025 | 3,250 | 125,306 | - | - | Stock Option (right to buy) | |
| Enliven Therapeutics Inc | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.48 per share. | 28 Apr 2025 | 3,250 | 26,250 | - | 2.5 | 8,060 | Common Stock |
| Enliven Therapeutics Inc | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 18.68 per share. | 28 Apr 2025 | 3,181 | 23,069 | - | 18.7 | 59,419 | Common Stock |
| Enliven Therapeutics Inc | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 19.12 per share. | 28 Apr 2025 | 69 | 23,000 | - | 19.1 | 1,319 | Common Stock |
| Enliven Therapeutics Inc | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.48 per share. | 27 Mar 2025 | 3,250 | 26,250 | - | 2.5 | 8,060 | Common Stock |
| Enliven Therapeutics Inc | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Mar 2025 | 3,250 | 128,556 | - | - | Stock Option (right to buy) | |
| Enliven Therapeutics Inc | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 21.33 per share. | 27 Mar 2025 | 3,250 | 23,000 | - | 21.3 | 69,321 | Common Stock |
| Enliven Therapeutics Inc | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Mar 2025 | 1,000 | 131,806 | - | - | Stock Option (right to buy) | |
| Enliven Therapeutics Inc | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 22.50 per share. | 24 Mar 2025 | 1,000 | 23,000 | - | 22.5 | 22,505 | Common Stock |
| Enliven Therapeutics Inc | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.48 per share. | 24 Mar 2025 | 1,000 | 24,000 | - | 2.5 | 2,480 | Common Stock |
| Enliven Therapeutics Inc | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.48 per share. | 04 Mar 2025 | 10,000 | 23,000 | - | 2.5 | 24,800 | Common Stock |
| Enliven Therapeutics Inc | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2025 | 10,000 | 132,806 | - | - | Stock Option (right to buy) | |
| Enliven Therapeutics Inc | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 20.41 per share. | 27 Feb 2025 | 3,250 | 13,000 | - | 20.4 | 66,327 | Common Stock |
| Enliven Therapeutics Inc | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Feb 2025 | 3,250 | 142,806 | - | - | Stock Option (right to buy) | |
| Enliven Therapeutics Inc | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.48 per share. | 27 Feb 2025 | 3,250 | 16,250 | - | 2.5 | 8,060 | Common Stock |
| Enliven Therapeutics Inc | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2025 | 171,000 | 171,000 | - | - | Stock Option (right to buy) | |
| Enliven Therapeutics Inc | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.48 per share. | 05 Feb 2025 | 1,000 | 14,000 | - | 2.5 | 2,480 | Common Stock |
| Enliven Therapeutics Inc | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 22.52 per share. | 05 Feb 2025 | 1,000 | 13,000 | - | 22.5 | 22,524 | Common Stock |
| Enliven Therapeutics Inc | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Feb 2025 | 1,000 | 146,056 | - | - | Stock Option (right to buy) | |
| Enliven Therapeutics Inc | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.48 per share. | 27 Jan 2025 | 3,250 | 16,250 | - | 2.5 | 8,060 | Common Stock |
| Enliven Therapeutics Inc | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 21.59 per share. | 27 Jan 2025 | 3,250 | 13,000 | - | 21.6 | 70,178 | Common Stock |
| Enliven Therapeutics Inc | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Jan 2025 | 3,250 | 147,056 | - | - | Stock Option (right to buy) | |
| Enliven Therapeutics Inc | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.48 per share. | 27 Dec 2024 | 3,350 | 3,350 | - | 2.5 | 8,308 | Common Stock |
| Enliven Therapeutics Inc | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Dec 2024 | 3,350 | 165,206 | - | - | Stock Option (right to buy) | |
| Enliven Therapeutics Inc | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 22.15 per share. | 27 Dec 2024 | 3,350 | 0 | - | 22.2 | 74,219 | Common Stock |
| Enliven Therapeutics Inc | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Dec 2024 | 900 | 164,306 | - | - | Stock Option (right to buy) | |
| Enliven Therapeutics Inc | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 22.51 per share. | 27 Dec 2024 | 900 | 0 | - | 22.5 | 20,255 | Common Stock |
| Enliven Therapeutics Inc | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.48 per share. | 27 Dec 2024 | 900 | 900 | - | 2.5 | 2,232 | Common Stock |
| Enliven Therapeutics Inc | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Dec 2024 | 13,000 | 155,556 | - | - | Stock Option (right to buy) | |
| Enliven Therapeutics Inc | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.48 per share. | 13 Dec 2024 | 13,000 | 13,000 | - | 2.5 | 32,240 | Common Stock |
| Enliven Therapeutics Inc | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Dec 2024 | 1,000 | 150,306 | - | - | Stock Option (right to buy) | |
| Enliven Therapeutics Inc | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 25.04 per share. | 13 Dec 2024 | 1,000 | 13,000 | - | 25.0 | 25,039 | Common Stock |
| Enliven Therapeutics Inc | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.48 per share. | 13 Dec 2024 | 1,000 | 14,000 | - | 2.5 | 2,480 | Common Stock |
| Enliven Therapeutics Inc | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.48 per share. | 27 Nov 2024 | 5,250 | 5,250 | - | 2.5 | 13,020 | Common Stock |
| Enliven Therapeutics Inc | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Nov 2024 | 5,250 | 168,556 | - | - | Stock Option (right to buy) | |
| Enliven Therapeutics Inc | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 24.78 per share. | 27 Nov 2024 | 4,250 | 1,000 | - | 24.8 | 105,313 | Common Stock |
| Enliven Therapeutics Inc | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 25.38 per share. | 27 Nov 2024 | 1,000 | 0 | - | 25.4 | 25,376 | Common Stock |
| Enliven Therapeutics Inc | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.48 per share. | 28 Oct 2024 | 6,250 | 6,250 | - | 2.5 | 15,500 | Common Stock |
| Enliven Therapeutics Inc | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Oct 2024 | 6,250 | 173,806 | - | - | Stock Option (right to buy) | |
| Enliven Therapeutics Inc | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 28.49 per share. | 28 Oct 2024 | 5,600 | 650 | - | 28.5 | 159,562 | Common Stock |
| Enliven Therapeutics Inc | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 29.11 per share. | 28 Oct 2024 | 650 | 0 | - | 29.1 | 18,922 | Common Stock |
| Enliven Therapeutics Inc | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Oct 2024 | 814 | 180,056 | - | - | Stock Option (right to buy) | |
| Enliven Therapeutics Inc | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.48 per share. | 18 Oct 2024 | 814 | 814 | - | 2.5 | 2,019 | Common Stock |
| Enliven Therapeutics Inc | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 30.00 per share. | 18 Oct 2024 | 814 | 0 | - | 30.0 | 24,422 | Common Stock |
| Enliven Therapeutics Inc | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 27.51 per share. | 04 Oct 2024 | 10,218 | 0 | - | 27.5 | 281,079 | Common Stock |
| Enliven Therapeutics Inc | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Oct 2024 | 10,218 | 182,140 | - | - | Stock Option (right to buy) | |
| Enliven Therapeutics Inc | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.48 per share. | 04 Oct 2024 | 10,218 | 10,218 | - | 2.5 | 25,341 | Common Stock |
| Enliven Therapeutics Inc | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Oct 2024 | 1,270 | 180,870 | - | - | Stock Option (right to buy) | |
| Enliven Therapeutics Inc | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.48 per share. | 04 Oct 2024 | 1,270 | 2,000 | - | 2.5 | 3,150 | Common Stock |
| Enliven Therapeutics Inc | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 27.51 per share. | 04 Oct 2024 | 1,270 | 0 | - | 27.5 | 34,935 | Common Stock |
| Enliven Therapeutics Inc | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Oct 2024 | 521 | 192,358 | - | - | Stock Option (right to buy) | |
| Enliven Therapeutics Inc | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 27.54 per share. | 01 Oct 2024 | 521 | 0 | - | 27.5 | 14,347 | Common Stock |
| Enliven Therapeutics Inc | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.48 per share. | 01 Oct 2024 | 521 | 521 | - | 2.5 | 1,292 | Common Stock |
| Enliven Therapeutics Inc | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.48 per share. | 27 Sep 2024 | 4,250 | 4,250 | - | 2.5 | 10,540 | Common Stock |
| Enliven Therapeutics Inc | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Sep 2024 | 4,250 | 194,879 | - | - | Stock Option (right to buy) | |
| Enliven Therapeutics Inc | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 24.27 per share. | 27 Sep 2024 | 4,250 | 0 | - | 24.3 | 103,161 | Common Stock |
| Enliven Therapeutics Inc | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Sep 2024 | 2,000 | 192,879 | - | - | Stock Option (right to buy) | |
| Enliven Therapeutics Inc | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 25.33 per share. | 27 Sep 2024 | 2,000 | 0 | - | 25.3 | 50,668 | Common Stock |
| Enliven Therapeutics Inc | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.48 per share. | 27 Sep 2024 | 2,000 | 2,000 | - | 2.5 | 4,960 | Common Stock |
| Enliven Therapeutics Inc | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 22.54 per share. | 27 Aug 2024 | 4,250 | 0 | - | 22.5 | 95,782 | Common Stock |
| Enliven Therapeutics Inc | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Aug 2024 | 4,250 | 199,129 | - | - | Stock Option (right to buy) | |
| Enliven Therapeutics Inc | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.48 per share. | 27 Aug 2024 | 4,250 | 4,250 | - | 2.5 | 10,540 | Common Stock |
| Enliven Therapeutics Inc | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.48 per share. | 31 Jul 2024 | 991 | 991 | - | 2.5 | 2,458 | Common Stock |
| Enliven Therapeutics Inc | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jul 2024 | 991 | 203,379 | - | - | Stock Option (right to buy) | |
| Enliven Therapeutics Inc | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 27.53 per share. | 31 Jul 2024 | 991 | 0 | - | 27.5 | 27,281 | Common Stock |
| Enliven Therapeutics Inc | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.48 per share. | 29 Jul 2024 | 5,250 | 5,250 | - | 2.5 | 13,020 | Common Stock |
| Enliven Therapeutics Inc | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jul 2024 | 5,250 | 204,370 | - | - | Stock Option (right to buy) | |
| Enliven Therapeutics Inc | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 26.67 per share. | 29 Jul 2024 | 5,189 | 61 | - | 26.7 | 138,378 | Common Stock |
| Enliven Therapeutics Inc | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 27.44 per share. | 29 Jul 2024 | 61 | 0 | - | 27.4 | 1,674 | Common Stock |
| Enliven Therapeutics Inc | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jul 2024 | 3,000 | 209,620 | - | - | Stock Option (right to buy) | |
| Enliven Therapeutics Inc | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 25.06 per share. | 12 Jul 2024 | 3,000 | 0 | - | 25.1 | 75,195 | Common Stock |
| Enliven Therapeutics Inc | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.48 per share. | 12 Jul 2024 | 3,000 | 3,000 | - | 2.5 | 7,440 | Common Stock |
| Enliven Therapeutics Inc | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Jun 2024 | 4,250 | 212,620 | - | - | Stock Option (right to buy) | |
| Enliven Therapeutics Inc | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.48 per share. | 27 Jun 2024 | 4,250 | 4,250 | - | 2.5 | 10,540 | Common Stock |
| Enliven Therapeutics Inc | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 22.58 per share. | 27 Jun 2024 | 1,830 | 1,140 | - | 22.6 | 41,313 | Common Stock |
| Enliven Therapeutics Inc | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 21.79 per share. | 27 Jun 2024 | 1,280 | 2,970 | - | 21.8 | 27,897 | Common Stock |
| Enliven Therapeutics Inc | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 23.43 per share. | 27 Jun 2024 | 1,140 | 0 | - | 23.4 | 26,711 | Common Stock |
| Enliven Therapeutics Inc | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.48 per share. | 28 May 2024 | 4,250 | 4,250 | - | 2.5 | 10,540 | Common Stock |
| Enliven Therapeutics Inc | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 May 2024 | 4,250 | 216,870 | - | - | Stock Option (right to buy) | |
| Enliven Therapeutics Inc | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 23.42 per share. | 28 May 2024 | 2,334 | 10 | - | 23.4 | 54,659 | Common Stock |
| Enliven Therapeutics Inc | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 22.89 per share. | 28 May 2024 | 1,906 | 2,344 | - | 22.9 | 43,628 | Common Stock |